论文部分内容阅读
原发性胆汁性肝硬化(PBC)虽然仍无完全有效的治疗,近年使用熊去氧胆酸和小剂量氨甲喋呤的无对照性试验结果显示其颇有前途。本文复习治疗PBC各种制剂的现状。青霉胺目前已有7项D-青霉胺治疗PBC的前瞻性对照试验。尽管初步报告提示青霉胺可改善肝功能和存活,但最后分析未能证明D-青霉胺治疗PBC有任何效果。D-青霉胺伴有严重副作用,在一些研究中高达30%,且引起数例死亡。硫唑嘌呤在2项前瞻性对照试验中,硫唑嘌呤剂量每日1～2 mg/kg,最初表明对PBC无疗效。5年
Although there is no complete and effective treatment of primary biliary cirrhosis (PBC), the results of an uncontrolled trial using ursodeoxycholic acid and low-dose methotrexate in recent years have shown promise. This review of the treatment of PBC various preparations of the status quo. Penicillamine There are currently seven prospective controlled trials of D-penicillamine in the treatment of PBC. Although preliminary reports suggest that penicillamine may improve liver function and survival, the final analysis failed to demonstrate any effect of D-penicillamine in the treatment of PBC. D-Penicillamine has serious side effects, up to 30% in some studies, and causes several deaths. Azathioprine Azathioprine dose of 1 to 2 mg / kg daily in two prospective controlled trials initially showed no effect on PBC. 5 years